Long-term outcome of retroperitoneal lymph node dissection in the management of testis cancer

Stephen D W Beck, Richard Foster

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

In low volume testicular cancer, (clinical stage A/B1) retroperitoneal lymph node dissection has maintained its therapeutic benefit while minimizing morbidity with the reduction of the surgical template from a full bilateral dissection to a unilateral nerve-sparring surgery. The optimal treatment for low stage disease is largely patient driven with surgery and surveillance considered the primary treatment modalities. In the post chemotherapy population, patients with complete radiographic resolution of retroperitoneal disease are observed at Indiana University as the relapse rate in this population is ∼5%. Residual masses after chemotherapy should be resected. A modified post chemotherapy dissection is adequate in low volume disease restricted to the primary landing zone of the affected testicle. In chemo-refractory disease, aggressive surgery provides a 5 year survival of 31% for patients with active cancer. Excluding chemo-naïve patients, late relapse disease is managed surgically with 50% being cured of disease.

Original languageEnglish
Pages (from-to)267-272
Number of pages6
JournalWorld Journal of Urology
Volume24
Issue number3
DOIs
StatePublished - Aug 2006

Fingerprint

Testicular Neoplasms
Lymph Node Excision
Drug Therapy
Dissection
Recurrence
Population
Testis
Therapeutics
Morbidity
Survival
Neoplasms

Keywords

  • Retroperitoneal lymph node dissection
  • Testicular cancer

ASJC Scopus subject areas

  • Urology

Cite this

Long-term outcome of retroperitoneal lymph node dissection in the management of testis cancer. / Beck, Stephen D W; Foster, Richard.

In: World Journal of Urology, Vol. 24, No. 3, 08.2006, p. 267-272.

Research output: Contribution to journalArticle

@article{b9431b087fa04b2b98a644664773d6b1,
title = "Long-term outcome of retroperitoneal lymph node dissection in the management of testis cancer",
abstract = "In low volume testicular cancer, (clinical stage A/B1) retroperitoneal lymph node dissection has maintained its therapeutic benefit while minimizing morbidity with the reduction of the surgical template from a full bilateral dissection to a unilateral nerve-sparring surgery. The optimal treatment for low stage disease is largely patient driven with surgery and surveillance considered the primary treatment modalities. In the post chemotherapy population, patients with complete radiographic resolution of retroperitoneal disease are observed at Indiana University as the relapse rate in this population is ∼5{\%}. Residual masses after chemotherapy should be resected. A modified post chemotherapy dissection is adequate in low volume disease restricted to the primary landing zone of the affected testicle. In chemo-refractory disease, aggressive surgery provides a 5 year survival of 31{\%} for patients with active cancer. Excluding chemo-na{\"i}ve patients, late relapse disease is managed surgically with 50{\%} being cured of disease.",
keywords = "Retroperitoneal lymph node dissection, Testicular cancer",
author = "Beck, {Stephen D W} and Richard Foster",
year = "2006",
month = "8",
doi = "10.1007/s00345-006-0060-8",
language = "English",
volume = "24",
pages = "267--272",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Long-term outcome of retroperitoneal lymph node dissection in the management of testis cancer

AU - Beck, Stephen D W

AU - Foster, Richard

PY - 2006/8

Y1 - 2006/8

N2 - In low volume testicular cancer, (clinical stage A/B1) retroperitoneal lymph node dissection has maintained its therapeutic benefit while minimizing morbidity with the reduction of the surgical template from a full bilateral dissection to a unilateral nerve-sparring surgery. The optimal treatment for low stage disease is largely patient driven with surgery and surveillance considered the primary treatment modalities. In the post chemotherapy population, patients with complete radiographic resolution of retroperitoneal disease are observed at Indiana University as the relapse rate in this population is ∼5%. Residual masses after chemotherapy should be resected. A modified post chemotherapy dissection is adequate in low volume disease restricted to the primary landing zone of the affected testicle. In chemo-refractory disease, aggressive surgery provides a 5 year survival of 31% for patients with active cancer. Excluding chemo-naïve patients, late relapse disease is managed surgically with 50% being cured of disease.

AB - In low volume testicular cancer, (clinical stage A/B1) retroperitoneal lymph node dissection has maintained its therapeutic benefit while minimizing morbidity with the reduction of the surgical template from a full bilateral dissection to a unilateral nerve-sparring surgery. The optimal treatment for low stage disease is largely patient driven with surgery and surveillance considered the primary treatment modalities. In the post chemotherapy population, patients with complete radiographic resolution of retroperitoneal disease are observed at Indiana University as the relapse rate in this population is ∼5%. Residual masses after chemotherapy should be resected. A modified post chemotherapy dissection is adequate in low volume disease restricted to the primary landing zone of the affected testicle. In chemo-refractory disease, aggressive surgery provides a 5 year survival of 31% for patients with active cancer. Excluding chemo-naïve patients, late relapse disease is managed surgically with 50% being cured of disease.

KW - Retroperitoneal lymph node dissection

KW - Testicular cancer

UR - http://www.scopus.com/inward/record.url?scp=33746517410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746517410&partnerID=8YFLogxK

U2 - 10.1007/s00345-006-0060-8

DO - 10.1007/s00345-006-0060-8

M3 - Article

VL - 24

SP - 267

EP - 272

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 3

ER -